Overview
Next-Generation, Once-Daily, Oral PDE4 Inhibitor Prodrugs for Inflammatory Disease
Next-Generation, Once-Daily, Oral PDE4 Inhibitor Prodrugs for Inflammatory Disease
Palisade Bio is a clinical-stage biopharmaceutical company advancing targeted oral therapies for inflammatory and fibrotic diseases. The Company’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed for targeted bioactivation in the ileum and colon, with the goal of improving pharmacology, tolerability and convenience for patients with inflammatory bowel disease.
Palisade Bio is now advancing towards two Phase 2 clinical studies in UC and Crohn’s disease (CD).
Palisade Bio is a clinical-stage biopharmaceutical company advancing targeted oral therapies for inflammatory and fibrotic diseases. The Company’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed for targeted bioactivation in the ileum and colon, with the goal of improving pharmacology, tolerability and convenience for patients with inflammatory bowel disease.
Palisade Bio is now advancing towards two Phase 2 clinical studies in UC and Crohn’s disease (CD).
Our Mission
Advance targeted oral therapies designed to improve treatment outcomes for patients with inflammatory and fibrotic diseases.
Our Vision
Transform validated biology into better tolerated, more convenient oral medicines for chronic inflammatory and fibrotic diseases.
Our Approach
Our Pipeline
Sign Up For Alerts